Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

Michael E. O'Dwyer; Ronan Swords; Arnon Nagler; Mary Frances McMullin; Philipp D. le Coutre; Stephen E. Langabeer; Alberto Alvarez-Iglesias; Hongxin Fan; Richard C. Woodman; Francis J. Giles; Eibhlin Conneally

doi:10.1016/j.leukres.2013.11.016

Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

Michael E. O'Dwyer
, Ronan Swords
, Arnon Nagler
, Mary Frances McMullin
, Philipp D. le Coutre
, Stephen E. Langabeer
, Alberto Alvarez-Iglesias
, Hongxin Fan
, Richard C. Woodman
, Francis J. Giles
, Eibhlin Conneally

Clinical Medicine and Population Health

Sylvester Comprehensive Cancer Center
Sheba Medical Center
Queen's University of Belfast
Charité – Universitätsmedizin Berlin
St James's Hospital
University of Texas Health Science Center at San Antonio
Novartis Institutes for Biomedical Research
Northwestern Medicine

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

10 Citations (Scopus)

Abstract

Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.

Original language	English
Pages (from-to)	310-315
Number of pages	6
Journal	Leukemia Research
Volume	38
Issue number	3
DOIs	https://doi.org/10.1016/j.leukres.2013.11.016
Publication status	Published - Mar 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CML BCR-ABL
Minimal residual disease
Molecular diagnostics
Nilotinib

Access to Document

10.1016/j.leukres.2013.11.016

Cite this

O'Dwyer, M. E., Swords, R., Nagler, A., McMullin, M. F., le Coutre, P. D., Langabeer, S. E., Alvarez-Iglesias, A., Fan, H., Woodman, R. C., Giles, F. J., & Conneally, E. (2014). Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. Leukemia Research, 38(3), 310-315. https://doi.org/10.1016/j.leukres.2013.11.016

@article{3f4c1414acb34a478b23fcfd19e80167,

title = "Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response",

abstract = "Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor{\texttrademark} PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88\% patients achieved MMR with 45\% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1\% and <10\% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor{\texttrademark} system merits further investigation in this setting.",

keywords = "CML BCR-ABL, Minimal residual disease, Molecular diagnostics, Nilotinib",

author = "O'Dwyer, \{Michael E.\} and Ronan Swords and Arnon Nagler and McMullin, \{Mary Frances\} and \{le Coutre\}, \{Philipp D.\} and Langabeer, \{Stephen E.\} and Alberto Alvarez-Iglesias and Hongxin Fan and Woodman, \{Richard C.\} and Giles, \{Francis J.\} and Eibhlin Conneally",

year = "2014",

month = mar,

doi = "10.1016/j.leukres.2013.11.016",

language = "English",

volume = "38",

pages = "310--315",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "3",

}

O'Dwyer, ME, Swords, R, Nagler, A, McMullin, MF, le Coutre, PD, Langabeer, SE, Alvarez-Iglesias, A, Fan, H, Woodman, RC, Giles, FJ & Conneally, E 2014, 'Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response', Leukemia Research, vol. 38, no. 3, pp. 310-315. https://doi.org/10.1016/j.leukres.2013.11.016

TY - JOUR

T1 - Nilotinib 300mg BID as frontline treatment of CML

T2 - Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

AU - O'Dwyer, Michael E.

AU - Swords, Ronan

AU - Nagler, Arnon

AU - McMullin, Mary Frances

AU - le Coutre, Philipp D.

AU - Langabeer, Stephen E.

AU - Alvarez-Iglesias, Alberto

AU - Fan, Hongxin

AU - Woodman, Richard C.

AU - Giles, Francis J.

AU - Conneally, Eibhlin

PY - 2014/3

Y1 - 2014/3

N2 - Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.

AB - Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.

KW - CML BCR-ABL

KW - Minimal residual disease

KW - Molecular diagnostics

KW - Nilotinib

UR - https://www.scopus.com/pages/publications/84894263290

U2 - 10.1016/j.leukres.2013.11.016

DO - 10.1016/j.leukres.2013.11.016

M3 - Article

SN - 0145-2126

VL - 38

SP - 310

EP - 315

JO - Leukemia Research

JF - Leukemia Research

IS - 3

ER -

Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this